Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BlackThorn Therapeutics

Request full access

Precision therapeutics for central nervous system disorders

San Francisco, United StatesFounded 2014Biotech & Life Sciences

About BlackThorn Therapeutics

BlackThorn Therapeutics was a clinical-stage biopharmaceutical company that focused on creating targeted therapeutics for neurobehavioral disorders. Founded around 2013-2015, the company was a spinout from The Scripps Research Institute. The founding scientific team included individuals such as Alex Tkachenko, Bill Martin, Ed Roberts, and Hugh Rosen. BlackThorn aimed to address the historical challenges in neuropsychiatric drug development, such as patient heterogeneity, by using a data-driven approach.

The company's core was its proprietary cloud-based computational psychiatry platform, known as PathFinder™ or INFORM. This platform integrated and analyzed multimodal data, including brain imaging and objective behavioral assessments, to identify dysfunctional brain circuits and objective neuromarkers. By doing so, BlackThorn sought to identify specific, biologically-based patient subgroups most likely to respond to a particular treatment, thus bringing a precision medicine approach to brain disorders. This strategy was intended to increase the probability of clinical trial success.

BlackThorn's business model was centered on advancing its pipeline of small-molecule drug candidates through clinical trials. The company raised significant capital, including a $40 million Series A in 2016 and a $76 million Series B in 2019, from prominent investors like ARCH Venture Partners, GV (formerly Google Ventures), and Johnson & Johnson Innovation. Its pipeline included several drug candidates targeting various receptors linked to neurobehavioral disorders. One lead program, BTRX-335140 (later navacaprant or NMRA-140), was a kappa opioid receptor (KOR) antagonist developed for major depressive disorder. Another program, BTRX-323511, was a vasopressin 1a receptor antagonist for conditions like autism spectrum disorder.

In 2020, BlackThorn Therapeutics was acquired by Neumora Therapeutics and became a foundational part of the new, larger company. Neumora, which launched in 2021 with $500 million in financing, integrated BlackThorn's team, platform, and clinical-stage assets to continue the mission of developing precision medicines for brain diseases. BlackThorn's lead drug candidates continued their development under Neumora's stewardship.

Source: Dealroom company data

At a glance

Status
Closed
Employees
2
Open positions
None listed
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Developer Tools, Biotechnology, Drug Development, Mental Health, Core AI, Spinout, Tech for Biotech and Pharma, Biotech and Pharma
Technology
Artificial Intelligence
Business model
Manufacturing
Client focus
B2C

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2019 $76M $304M Polaris Partners · Vertex Holdings · Premier Partners · Altitude Life Science Ventures —
GRANTOther financing Jun 2017 $8M — National Institute of Neurological Disorders and Stroke —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

BlackThorn Therapeutics website traffic

Latest recorded traffic for BlackThorn Therapeutics is 260 monthly website visits, down 61.2% over the last three months. BlackThorn Therapeutics's team grew 0% over the past year.

Latest monthly visits260 3-month web change-61.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

BlackThorn Therapeutics in the San Francisco ecosystem

Live from Dealroom

The BlackThorn Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institute of Neurological Disorders and Stroke

Series A11 investors entered at this stage

Other known investors1 additional known investor

  • Scripps Translational Science Institute
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BlackThorn Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BlackThorn Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.